| Name | Title | Contact Details |
|---|
Cherry Health is an independent, non-profit Federally Qualified Health Center (FQHC) with a primary focus of providing high quality health services to those who have little or no access to health care, regardless of income or insurance status. Services provided by Cherry Health include primary care, women`s health, pediatrics, dental, vision, behavioral health, mental health, correctional health, five school based health centers and employee assistance for employers. Cherry Health provides services to all individuals, regardless of their ability to pay. A sliding fee payment scale based on income and family size is available to those without insurance. Medicaid and Healthy Michigan are accepted, as are many other insurances. Established in 1988, Cherry Health is the largest FQHC in the state of Michigan serving Barry, Eaton, Kent, Montcalm and Wayne counties at more than 20 locations, 14 of which are primary care Federally Qualified Health Center sites, Cherry Health employs over 800 employees and a network of over 60 physicians and mid-level providers specializing in primary care/family medicine, pediatrics, internal medicine, obstetrics/gynecology, optometry and psychiatry. Additionally, Cherry Health runs a school linked program active in 70 public schools offering both vision and dental care.
Spryance Inc is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Medical Assurance Company Of Mississippi is a Ridgeland, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
OmnisSYS is a Greenville, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.